Compare AMKR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | RDY |
|---|---|---|
| Founded | 1968 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.6B |
| IPO Year | 1998 | N/A |
| Metric | AMKR | RDY |
|---|---|---|
| Price | $50.91 | $13.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $36.71 | $16.90 |
| AVG Volume (30 Days) | ★ 3.7M | 1.1M |
| Earning Date | 02-09-2026 | 01-21-2026 |
| Dividend Yield | ★ 0.63% | 0.52% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 1.24 | 0.79 |
| Revenue | ★ $6,449,053,000.00 | $3,851,623,984.00 |
| Revenue This Year | $7.41 | $6.12 |
| Revenue Next Year | $9.14 | $2.58 |
| P/E Ratio | $42.52 | ★ $17.45 |
| Revenue Growth | 0.14 | ★ 14.10 |
| 52 Week Low | $14.03 | $12.26 |
| 52 Week High | $53.53 | $16.17 |
| Indicator | AMKR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 69.78 | 31.09 |
| Support Level | $39.47 | $13.66 |
| Resistance Level | $53.53 | $14.12 |
| Average True Range (ATR) | 1.82 | 0.17 |
| MACD | 0.96 | -0.07 |
| Stochastic Oscillator | 80.47 | 1.05 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.